We create the future of health.

We create the future of health

The Bio Convergence company

We can create human tissues and organs using cells from our own bodies, paving the way to make us our own organ donors, reducing organ rejection and solve the problem with lack of donors.

We can improve healing by developing new, better and individualized treatments, even faster than before.

We can save lives with faster and more accurate methods for drug discovery, while eliminating the unnecessary use of animal testing.

We can prevent outbreaks and proactively plan around new diseases with better diagnostics.

Bico by the numbers - Q2

Future. Forward. Fast

  • Net sales Q2 2021
    0 MUSD
  • Organic growth Q2 2021
    0 %
  • Employees
    0 +
  • Labs
    0 +
  • Publications
    0 +
  • Countries
    0 +

We are BICO

We consist of several subsidiaries divided into the business areas Bioprinting, Biosciences and Bioautomation. Together, we provide technology, products and services to create, understand and master biology.

Where life and technology becomes one

Bio Convergence

The art of combining the power of biology, engineering and computer science to extend the boundaries of what’s possible to give people better and healthier lives.

We see a future where robotics, artificial intelligence, advanced genomics and bioprinting come together to fundamentally shift the global healthcare industry.

Making the seemingly impossible, possible

Focusing on bioprinting, multiomics, cell line development and diagnostics, we enable researchers to grow cells in 3D environments, conduct high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.

Industry-leading experts​

Our products are used in more than 2,000 laboratories including the world’s top 20 leading pharmaceutical companies, in more than 65 countries and have been cited in more than 1,850 publications.

Making the seemingly impossible, possible

Focusing on bioprinting, multiomics, cell line development and diagnostics, we enable researchers to grow cells in 3D environments, conduct high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.

Industry-leading experts​

Our products are used in more than 2,000 laboratories including the world’s top 20 leading pharmaceutical companies, in more than 65 countries and have been cited in more than 9,000 publications.

Investor

Follow our financial story as we create the future of health.

Investor page

Q2 Report

Read our latest quarterly report.

Download

Earnings call

August 18, 08:00 (EST)/14:00 (CEST)

Presentation earnings call

Video on demand

press releases

Calendar

November 10, 2021Q3 report 2021
February 23, 2022Year-end report 2021
March 16, 2022Annual report 2021
Message from the CEO

Unleashing the power of Bio Convergence

Erik Gatenholm, CEO at BICO, decided to change the group company name to better reflect the strategic bio convergence agenda and emphasize that the company comprises several subsidiaries divided into three business areas. Now, the journey begins to build a world-famous brand.

"We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future.

Erik Gatenholm, CEO, BICO
Message from the CEO

Unleashing the power of Bio Convergence

Erik Gatenholm, CEO at BICO, decided to change the group company name to better reflect the strategic bio convergence agenda and emphasize that the company comprises several subsidiaries divided into three business areas. Now, the journey begins to build a world-famous brand.

"We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future.

Erik Gatenholm, CEO, BICO

Q&A

    • Why did you change your name to BICO?
    • Since 2016, we have built a world-leading Group that offers something unique - namely a revolution in Bio Convergence. This concept is guiding for us and therefore we have changed the name of the parent company from CELLINK to BICO. The new name reflects our business strategic agenda within Bio Convergence and emphasizes that we are a Group consisting of 11 subsidiaries divided into three strong business areas: Bioprinting, Biosciences and Bioautomation.
    • What does BICO mean?
    • It is an abbreviation for BIo COnvergence which means that we combine the forces of biology, engineering and computer science to expand the boundaries of what is possible - to give people a better and healthier life. We see a future where robotics, artificial intelligence, advanced genomics and bioprinting are brought together to, together, advance the global health industry.
    • What is BICO?
    • BICO is the parent company for the Group with Group-wide functions and with a focus on delivering on the agenda for Bio Convergence, identifying synergies, developing the offering and technologies and contributing to the development of the Group's subsidiaries. Together, the Group will have clear focus on continuing to develop the business. Organizationally, BICO is divided into three business areas: Bioprinting, Biosciences and Bioautomation. Each business area includes the Group companies: CELLINK Bioprinting, MatTek, Visikol and Nanoscribe (Bioprinting), Cytena, Cytena BPS, Dispendix and Discover Echo (Biosciences) and SCIENION, CELLENION and Ginolis (Bioautomation).
    • What happens to CELLINK?
    • CELLINK is and remains a world-leading brand in 3D bioprinting. CELLINK will be a wholly owned subsidiary of BICO and will continue its goal-oriented work with a focus on bioprinting of human organs and tissues. For more information about CELLINK's innovative product portfolio and offer in 3D bioprinting, please visit www.cellink.com
    • If I already have shares or options do I need to do something?
    • This is an administrative matter and shareholders do not need to take any action
    • What should I do if I want to buy shares in BICO?
    • You enter BICO instead of CLNK. The company’s ISIN code and order book ID are unchanged.
    • What should I do if I want to sell shares in BICO?
    • You enter BICO instead of CLNK when you choose to sell shares from your depository.
    • Where can I find the latest interim report?
    • The Q2 report is available under the Financial Statements tab at bico.com/investors. Click here to download it immediately.
    • Where can I find historical reports and presentations?
    • All financial reports, presentations and annual reports are available under the financial reports tab at bico.com/investors. Click here to visit the section.
    • I subscribe to press releases and reports from CELLINK do I have to fill in again for BICO?
    • No, all subscribers have been transferred, and you will continue to receive information from BICO instead of CELLINK. If you wish to subscribe to our press releases, reports and annual reports, click here to access the registration form.
    • Who can I reach out to if I have any questions?
    • You are always welcome to contact ir@bico.com. We are here for you and to answer your questions.

Join the revolution

Bring your values to do work that matters—not just to you, but to the world

Contact us

    • Investor relations

    • Isabelle Ljunggren, Head of Communications
    • Email: il@bico.com
    • Sales

    • Visit our subsidiaries' websites to explore our product offering.

Press room

Press Releases

Financial Reports

Calendar

November 10, 2021Q3 report 2021
February 23, 2022Year-end report 2021
March 16, 2022Annual report 2021